{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:01:48Z","timestamp":1790240508410,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Linezolid may be an option for severe group A Streptococcus (GAS) infections based on its potent in vitro activity and antitoxin effects, but clinical data supporting its use over clindamycin are limited. This study evaluated treatment outcomes in patients with severe GAS skin and soft tissue infections who received either linezolid or clindamycin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center cohort study examined patients with GAS isolated from blood and\/or tissue cultures with invasive soft tissue infection or necrotizing fasciitis who underwent surgical debridement and received linezolid or clindamycin for at least 48 hours. The primary outcome was percentage change in Sequential Organ Failure Assessment (SOFA) score from baseline through 72 hours of hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After adjustment for time to first surgical intervention among patients with a baseline SOFA score &amp;gt;0 (n = 23 per group), there was no difference in reduction of SOFA score over the first 72 hours in patients receiving clindamycin vs linezolid. In the entire cohort (n = 26, clindamycin; n = 29, linezolid), there was no difference in inpatient mortality (2% vs 1%) or any secondary outcomes, including duration of vasopressor therapy, intensive care unit length of stay, and antibiotic-associated adverse drug events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was no difference in reduction of critical illness as measured by SOFA score between baseline and 72 hours among patients treated with clindamycin vs linezolid. Given its more favorable side effect profile, linezolid may be a viable option for the treatment of serious GAS infections and should be further studied.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofad588","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T18:36:30Z","timestamp":1700678190000},"source":"Crossref","is-referenced-by-count":30,"title":["Comparison of Adjuvant Clindamycin vs Linezolid for Severe Invasive Group A\n                    <i>Streptococcus<\/i>\n                    Skin and Soft Tissue Infections"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6644-6684","authenticated-orcid":false,"given":"Emily L","family":"Heil","sequence":"first","affiliation":[{"name":"Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Atalla","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Basappa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Massachusetts Memorial Medical Center , Worcester, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minu","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Medicine, Milton S. Hershey Medical Center , Hershey, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunuk","family":"Seung","sequence":"additional","affiliation":[{"name":"Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Kristie","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M","family":"Schrank","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"2023122900462864800_ofad588-B1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/CMR.00101-13","article-title":"Disease manifestations and pathogenic mechanisms of group A Streptococcus","volume":"27","author":"Walker","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2023122900462864800_ofad588-B2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/toxins11060332","article-title":"The role of streptococcal and staphylococcal exotoxins and proteases in human necrotizing soft tissue infections","volume":"11","author":"Shumba","year":"2019","journal-title":"Toxins (Basel)"},{"key":"2023122900462864800_ofad588-B3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1128\/CMR.00104-12","article-title":"Staphylococcal and streptococcal superantigen exotoxins","volume":"26","author":"Spaulding","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2023122900462864800_ofad588-B4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(09)70066-0","article-title":"Gram-positive toxic shock syndromes","volume":"9","author":"Lappin","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2023122900462864800_ofad588-B5","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023122900462864800_ofad588-B6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1473-3099(20)30523-5","article-title":"Effectiveness of adjunctive clindamycin in \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study","volume":"21","author":"Babiker","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023122900462864800_ofad588-B7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/INF.0000000000001442","article-title":"Macrolide and clindamycin resistance in group A streptococci isolated from children with pharyngitis","volume":"36","author":"DeMuri","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2023122900462864800_ofad588-B8","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/cid\/ciab575","article-title":"Patterns of antibiotic nonsusceptibility among invasive group A Streptococcus infections\u2014United States, 2006\u20132017","volume":"73","author":"Fay","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023122900462864800_ofad588-B9","doi-asserted-by":"crossref","first-page":"e4592","DOI":"10.1093\/cid\/ciaa976","article-title":"Outcomes of \u03b2-hemolytic streptococcal necrotizing skin and soft-tissue infections and the impact of clindamycin resistance","volume":"73","author":"Horn","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023122900462864800_ofad588-B10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/jac\/dkf192","article-title":"Virulence factor expression by gram-positive cocci exposed to subinhibitory concentrations of linezolid","volume":"50","author":"Gemmell","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2023122900462864800_ofad588-B11","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1128\/AAC.47.5.1752-1755.2003","article-title":"Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release","volume":"47","author":"Coyle","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122900462864800_ofad588-B12","first-page":"5720708","article-title":"Successful treatment of necrotizing fasciitis and streptococcal toxic shock syndrome with the addition of linezolid","volume":"2017","author":"Rac","year":"2017","journal-title":"Case Rep Infect Dis"},{"key":"2023122900462864800_ofad588-B13","doi-asserted-by":"crossref","first-page":"ofad258","DOI":"10.1093\/ofid\/ofad258","article-title":"Clindamycin plus vancomycin versus linezolid for treatment of necrotizing soft tissue infection","volume":"10","author":"Dorazio","year":"2023","journal-title":"Open Forum Inf Dis"},{"key":"2023122900462864800_ofad588-B14","article-title":"Increased incidence of scarlet fever and invasive group A Streptococcus infection\u2014multi-country","author":"World Health Organization"},{"key":"2023122900462864800_ofad588-B15","article-title":"Centers for Disease Control and Prevention. Surveillance for group A strep disease"},{"key":"2023122900462864800_ofad588-B16","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3201\/eid2809.212129","article-title":"Increasing incidence of invasive group A Streptococcus disease, Idaho, USA, 2008\u20132019","volume":"28","author":"Dunne","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2023122900462864800_ofad588-B17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/cid\/ciu304","article-title":"Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group A streptococcal infections","volume":"59","author":"Carapetis","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023122900462864800_ofad588-B18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.1993.03500030088038","article-title":"Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition.","volume":"269","author":"Working Group on Severe Streptococcal Infections","year":"1993","journal-title":"JAMA"},{"key":"2023122900462864800_ofad588-B19","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit Care Med"},{"key":"2023122900462864800_ofad588-B20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1097\/01.CCM.0000129486.35458.7D","article-title":"The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections","volume":"32","author":"Wong","year":"2004","journal-title":"Crit Care Med"},{"key":"2023122900462864800_ofad588-B21","author":"Clinical and Laboratory Standards Institute"},{"key":"2023122900462864800_ofad588-B22","author":"Clinical and Laboratory Standards Institute"},{"key":"2023122900462864800_ofad588-B23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/cid\/ciac720","article-title":"Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group A streptococcal necrotizing soft tissue infection and toxic shock syndrome? A focused debate","volume":"76","author":"Cort\u00e9s-Penfield","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023122900462864800_ofad588-B24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bcpt.13123","article-title":"Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases","volume":"124","author":"Choi","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2023122900462864800_ofad588-B25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-020-02990-1","article-title":"Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic\/pharmacodynamic analysis","volume":"77","author":"Gatti","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2023122900462864800_ofad588-B26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jgar.2020.04.032","article-title":"Emerging erythromycin and clindamycin resistance in group A streptococci: efficacy of linezolid and tedizolid in experimental necrotizing infection","volume":"22","author":"Bryant","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2023122900462864800_ofad588-B27","first-page":"269","article-title":"Clindamycin affects group A Streptococcus virulence factors and improves clinical outcome","volume":"215","author":"Andreoni","year":"2017","journal-title":"J Infect Dis"},{"key":"2023122900462864800_ofad588-B28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12879-022-07135-6","article-title":"The importance of intravenous immunoglobulin treatment in critically ill patients with necrotizing soft tissue infection: a retrospective cohort study","volume":"22","author":"Hofmaenner","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2023122900462864800_ofad588-B29","first-page":"877","article-title":"Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity score-matched analysis from 130 US hospitals","volume":"64","author":"Kadri","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023122900462864800_ofad588-B30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s13054-019-2665-5","article-title":"The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort","volume":"23","author":"Karakike","year":"2019","journal-title":"Crit Care"},{"key":"2023122900462864800_ofad588-B31","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1186\/cc7160","article-title":"Evaluation of SOFA-based models for predicting mortality in the ICU: a systematic review","volume":"12","author":"Minne","year":"2008","journal-title":"Crit Care"},{"key":"2023122900462864800_ofad588-B32","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/jama.286.14.1754","article-title":"Serial evaluation of the SOFA score to predict outcome in critically ill patients","volume":"286","author":"Ferreira","year":"2001","journal-title":"JAMA"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad588\/53793514\/ofad588.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/12\/ofad588\/54914500\/ofad588.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/12\/ofad588\/54914500\/ofad588.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T20:07:52Z","timestamp":1703794072000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad588\/7450154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad588","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,11,24]]},"article-number":"ofad588"}}